key: cord-0907224-8lpr4den
authors: Rubio, Maria Caridad; Sanchez, Lizet; Abreu-Ruíz, Gisela; Bermejo-Bencomo, Walkiria; Crombet, Tania; Lage, Agustin
title: COVID-19 AND CANCER IN CUBA
date: 2020-08-07
journal: Semin Oncol
DOI: 10.1053/j.seminoncol.2020.07.009
sha: f5e160be702d1df2472c5eb634c70df860cbea28
doc_id: 907224
cord_uid: 8lpr4den

The COVID-19 pandemic has called attention to the contribution of comorbidities, including cancer and brought additional challenges to previously existing programs for cancer treatment and control. The COVID-19 pandemic in Cuba was addressed through an integrated all-society action plan that to date has been largely successful with a low incidence of COVID-19 and mortality rates several-fold lower than worldwide averages. Despite downsizing many other health components all oncology services were maintained. Between March 11, when the first case was detected, until July 23, Cuba reported 2449 cases of COVID-19 that included 28 (1.14%) with a diagnosis of cancer. Distribution amongst cancer diagnoses did not deviate from that expected according to cancer epidemiology in Cuba. However, although the probability of getting infected with the coronavirus for a cancer patient (0.012%), was not higher than that of the general population (0.020%), nine of the 28 (32.1%) died, a lethality higher than that of COVID-19 patients without cancer (3.5%) a difference that is statistically significant (p<0.001). We argue that going forward scientific research on the relationship of aging, inflammation and cancer, including identification of biomarkers and the development of novel therapeutic interventions, should become one of the priorities in the post-COVID agenda of both oncologists and infectious disease scientists.

incidence of COVID-19 and mortality rates several-fold lower than worldwide averages. Despite downsizing many other health components all oncology services were maintained. Between March 11, when the first case was detected, until July 23, Cuba reported 2449 cases of COVID-19 that included 28 (1.14%) with a diagnosis of cancer.

Distribution amongst cancer diagnoses did not deviate from that expected according to cancer epidemiology in Cuba. However, although the probability of getting infected with the coronavirus for a cancer patient (0.012%), was not higher than that of the general population (0.020%), nine of the 28 (32.1%) died, a lethality higher than that of COVID-19 patients without cancer (3.5%) a difference that is statistically significant (p<0.001). We argue that going forward scientific research on the relationship of aging, inflammation and cancer, including identification of biomarkers and the development of novel therapeutic interventions, should become one of the priorities in the post-COVID agenda of both oncologists and infectious disease scientists.

The COVID-19 pandemic has had a dual impact on the treatment of cancer. First, the higher incidence of COVID lethality in older patients has called attention to the contribution of comorbidities, including cancer. Second, the demands the pandemic has placed on health systems have in turn brought additional challenges to previously existing programs for cancer treatment and control. Since the beginning of the pandemic, the attention of the worldwide scientific community to COVID-19 has produced more than 15,000 manuscripts. A multinational study that reported outcomes in more than 900 patients with a diagnosis of cancer and COVID-19 in Spain, Canada and the USA (1) found a lethality rate above 13% for patients diagnosed with COVID- The COVID-19 pandemic in Cuba was addressed through an integrated all-society action plan, which was designed and implemented before the first cases appeared. The COVID-19 action plan was managed, on a daily basis, by the top authorities of the government and to date has been largely successful: the transmission of the disease has been controlled and the incidence of COVID-19 and the mortality rates have been kept at levels several-fold lower than worldwide averages. A description of the Cuban strategy and processes for COVID-19 has been recently published (4; available in supplementary material). Between March 11, when the first case was detected, until July 23, Cuba reported 2449 cases of COVID-19. Among them 28 (1.14%) had cancer as a comorbidity. Distribution amongst cancer diagnoses did not deviate from that expected according to cancer epidemiology in Cuba. Lung cancer was the most frequent cancer diagnosis, with 6 cases (21.4%), followed by head and neck cancer with 4 cases (14.3%), and breast cancer with 3 cases (10.7%). There were also cases two diagnoses each of esophageal, prostate, bladder and ovarian cancer, and one diagnosis of cervical, colon, pancreatic, and kidney cancer, and one case each of leukemia, lymphoma and multiple myeloma.

As the epidemic in Cuba to date has been well contained, no statistically significant conclusion can be extracted from these descriptive data.

However, some preliminary hints can be discerned, and these provide insights for future research. The first is that the probability of getting infected with the coronavirus for a cancer patient (0.012%), as calculated according to our best estimates of cancer prevalence, is not higher than that of the general population (0.020%). It could be even slightly lower, which might be expected given the heightened isolation and protection of cancer patients. However, the second observation, one that concerns lethality is less encouraging. Of the 28 patients with a diagnosis of COVID-19 who had a concurrent cancer diagnosis, nine (32.1%) died, a lethality higher than that of COVID-19 patients without cancer (3.5%). This difference in lethality is statistically significant (p<0.001).

Furthermore, it does not appear this effect of cancer on COVID-19 lethality can be explained by age. In the subgroup above 60 years of age, lethality was 13.5% for patients not having cancer (including those with other comorbidities), but 41.2% for COVID-19 patients older than 60 years having a concurrent cancer diagnosis.

Cognizant that the small numbers of patients requires us to be careful with regards to any generalizations, our data suggest that a diagnosis of cancer does not lead to a higher probability of getting infected with coronavirus, but does introduce a higher probability of severe evolution and death if infected. The small size of the sample does not allow us to make any adjustments by type of treatment.

Our experience provides some insight that might be considered going forward. The incidence of cancer will continue to increase driven by the aging of the population.

Moreover, for a variety of cancer diagnoses, the disease is becoming a more chronic illness, that while not amenable to cure, can often be controlled for several years (6) . 

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

La Habana: MINSAP; 2020

Back and forth between cancer treatment and cancer control programs: Insights from the Cuban experience

Gestión gubernamental y ciencia cubana en el enfrentamiento a la COVID-19

Actions adopted in Cuba for cáncer patients during the COVID-19 epidemics

Control of Advanced Cancer: The road to chronicity

Biomodulina T partially restores immunosenescent CD4 and CD8 T cell compartments in the elderly

HeberFERON, a new formulation of IFNs with improved pharmacodynamics: Perspective for cancer treatment

Therapeutic Targeting of CD6 in Autoimmune Diseases: A Review of Cuban Clinical Studies with the Antibodies IOR-T1 and Itolizumab